Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

87.96 +0.65 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 501,543
Open 87.31
Bid (Size) 86.49 (3)
Ask (Size) 88.11 (5)
Prev. Close 87.31
Today's Range 86.37 - 88.36
52wk Range 37.66 - 94.45
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
 
Via Benzinga

Performance

YTD
+74.94%
+74.94%
1 Month
+3.46%
+3.46%
3 Month
+35.36%
+35.36%
6 Month
+73.73%
+73.73%
1 Year
+106.72%
+106.72%

More News

Read More
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is a Stock Spotlight on 5/25
Via Investor Brand Network
Why Shares of Annexon Are Plummeting Thursday
Via The Motley Fool
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
Via Investor's Business Daily
Why These 3 Nasdaq Stocks Buckled Today
Via The Motley Fool
Are Small Caps a Harbinger of Market Declines?
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Earnings Preview: Apellis Pharmaceuticals
Via Benzinga
Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations
Via Benzinga
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
Via The Motley Fool
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Via Investor's Business Daily
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
Via Benzinga
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.